Competing trials are under way that may show that the benefits of SGLT2 inhibitors in heart failure are a class effect. Sodium glucose cotransporter 2 (SGLT2) inhibitors, first approved to treat type ...

Dapagliflozin improved eGFR slope in patients with CKD associated with ADPKD, but it resulted in an increase in kidney volume. Dapagliflozin may exert a protective effect on kidney function in ...

Objectives: The efficacy of dapagliflozin as add-on therapy to metformin has been assessed in randomized trials. However, its effectiveness has not been assessed in a US real-world setting. Methods: ...

Regardless of diabetes status, patients with chronic kidney disease (CKD) have better renal and cardiovascular outcomes as well as a lower chance of dying when dapagliflozin (Farxiga; AstraZeneca) is ...

PHILADELPHIA, PA—Dapagliflozin (Farxiga; AstraZeneca), originally developed for the treatment of type 2 diabetes, has a broad, positive impact across various subsets of patients with chronic heart ...

Please provide your email address to receive an email when new articles are posted on . High-risk patients with diabetes who were treated with dapagliflozin had a decrease in the incidence of atrial ...

Type 2 Diabetes (T2D) is a major public health challenge, with India ranking second globally in prevalence. [1] The ...

Please provide your email address to receive an email when new articles are posted on . The benefit of dapagliflozin was consistent among adults with HF with and without gout and was associated with ...

Forxiga™ (dapagliflozin), First-In-Class SGLT2 That Works Independently of Insulin, Now Approved in European Union for Treatment of Type 2 Diabetes Forxiga, a once-daily oral agent, provides ...

Amit Bansal, Managing Director, Theon Pharmaceuticals Ltd says this fixed-dose combination tablet of linagliptin, dapagliflozin, and metformin hydrochloride is a suitable option for the following ...

Glycemic control for many patients with type 2 diabetes mellitus (T2DM) is elusive, and the adverse effects of treatment, including hypoglycemia and weight gain, are partially culpable. Until recently ...